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Abstract
Background and objective There are inconsistent data
of the cytochrome P450 1A1 (CYP1A1) Ile462Val
(rs1048943) single nuclear polymorphism (SNP) as a
genetic susceptibility factor for cervical cancer in various
populations. Moreover, little is known about the interaction
of this SNP with other risk factors, including contraceptive
use, postmenopausal status, parity, and tobacco smoking.
Methods Polymerase chain reaction-restriction fragment
length polymorphism was used to study the prevalence of
the CYP1A1 Ile462Val SNP in women with cervical cancer
(n = 456) and controls (n = 495).
Results Logistic regression analysis adjusting for age,
parity, oral contraceptive use, tobacco smoking, and men-
opausal status demonstrated that that the CYP1A1 Ile/Val
polymorphism was not associated with an increased risk of
cervical cancer in all patients. The adjusted odds ratio (OR)
for patients with the Ile/Val genotype vs. Ile/Ile genotype
was 1.539 (95 % confidence interval [CI] 0.932–2.541,
p = 0.091). However, an increase in cervical cancer risk
was seen among patients with a positive history of tobacco
smoking and parity. The adjusted OR for positive history of
tobacco smoking with the Ile/Val vs. Ile/Ile genotypes was
2.978 (95 % CI 1.382–6.418, p = 0.0052). The adjusted
OR for parity with the Ile/Val vs. Ile/Ile genotype was
1.739 (95 % CI 1.006–3.009, p = 0.0472).
Conclusion Our genetic study suggests that the CYP1A1
Ile462Val SNP may be a risk factor for cervical cancer
among patients with a positive history of tobacco smoking
and parity.
1 Introduction
Cervical cancer is the third most common type of cancer in
women worldwide [1]. This cancer develops slowly;
starting from a precancerous dysplasia designated cervical
intraepithelial neoplasia (CIN) that may further develop to
invasive cervical carcinoma [2, 3]. Almost all cervical
cancers are caused by the human papilloma virus (HPV),
which is considered the primary etiologic factor of this
cancer [3, 4]. Some oncogenic HPV oncoproteins, includ-
ing E6 and E7, cause a defect in the host’s innate and
adaptive immunity and change the apoptotic pathway,
leading to immortalization of normal cervical epithelial
cells [2, 4]. Apart from HPV, multiparity, oral contracep-
tive use, tobacco smoking, and environmental insults have
been recognized as secondary risk factors [5].
Cytochrome P450 1A1 (CYP1A1) belongs to the CYP1
family and is involved in the metabolism of endogenous
molecules and xenobiotics [6]. The actions of CYP1A1
include aryl hydrocarbon hydroxylase activity, which is the
first step in the metabolism of tobacco polycyclic aromatic
hydrocarbons, leading to their carcinogenic activation [7].
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CYP1A1 also participates in the metabolism of estrogen
[8]. Therefore, the activity of CYP1A1 may influence cells
via at least two distinct pathways, i.e., smoking and
estrogen, on cervical carcinogenesis [5].
Two single nucleotide polymorphisms (SNPs) in the
CYP1A1 gene have been studied as risk factors of cervical
carcinogenesis: T3801C (rs4646903) and A2455G
(rs1048943) [9]. The T3801C SNP is located in the 30
untranslated region and A2455G corresponds to the sub-
stitution Ile462Val in exon 7. These two SNPs have been
suggested as being in linkage disequilibrium (LD) in
Caucasian populations [9]. The role of both of these SNPs
in CYP1A1 as risk factors in cervical cancer development
in different ethnicities is still disputable [10–13]. More-
over, little is known about the interaction of these SNPs
with the other known risk factors of cervical cancer. We
evaluated the CYP1A1 Ile462Val genotype and allele fre-
quencies in patients with cervical cancer (n = 456) and
controls (n = 495) in the Polish population, stratified based
on contraceptive use, postmenopausal status, parity, and
tobacco smoking.
2 Patients and Methods
2.1 Patients and Controls
The patients included 456 women with histologically
determined cervical carcinoma according to the Interna-
tional Federation of Gynecology and Obstetrics. All
women were enrolled between April 2007 and December
2012 at the Department of Radiotherapy, Greater Poland
Cancer Center in Poznan, Poland (Table 1). The control
group included 285 unrelated healthy female volunteers
who were matched by age to the patients. The controls
were enrolled during medical examination at the University
Hospital, Clinic of Gynecological Surgery at Poznan Uni-
versity of Medical Science (Table 1). Data about parity,
oral contraceptive use, tobacco smoking, and menopausal
status were obtained during the clinical interview. Patients
and controls were Caucasian, enrolled from the Wie-
lkopolska (Greater Poland) area of Poland. Patients and
controls provided written informed consent. The study was
approved by the Local Ethical Committee of Poznan Uni-
versity of Medical Sciences.
2.2 Genotyping
DNA was obtained from peripheral leukocytes employing
a salting-out procedure. Identification of the CYP1A1
Ile462Val (rs1048943) polymorphic variant was performed
by polymerase chain reaction-restriction fragment length
polymorphism. The CYP1A1 Ile462Val DNA fragment
was amplified employing the primers 50 ACCCATCTG
AGTTCCTACC 30 and 50 TCCACCTTCACGCCCAGT 30.
The PCR-amplified fragments of CYP1A1 that were 199 bp
in length were isolated and digested with endonuclease
HpyCH4III (50 ACNGT 30) from the New England BioLabs
(Ipswich, USA). The CYP1A1 Val allele was cleaved into
116-bp and 83-bp fragments, whereas the CYP1A1 Ile






Mean agea (years) ± SD 52.4 ± 9.8 51.9 ± 10.2














Histologic type, n (%)
Squamous cell carcinoma 384 (84.2)
Adenocarcinoma 56 (12.3)
Other 16 (3.5)
Parity , n (%)
Never 51 (11.2) 56 (11.31)
Ever 405 (88.8) 439 (88.6)
Oral contraceptive pill use, n (%)
Never 248 (54.4) 278 (56.2)
Ever 208 (45.6) 217 (43.8)
Tobacco smoking, n (%)
Never 295 (64.7) 331 (66.9)
Ever 161 (35.3) 164 (33.1)
Menopausal status, n (%)
Premenopausal 159 (34.9) 190 (38.4)
Postmenopausal 297 (65.1) 305 (61.6)
HPV genotypesb, n (%)
16 and 18 311 (68.2)
16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 68
352 (77.2)
a Age at first diagnosis
b HPV genotypes were determined by Cobas HPV Test Roche
Molecular Systems, Inc. (Alameda, CA, USA)
HPV human papilloma virus, SD standard deviation
446 A. Roszak et al.
allele remained uncut. Presence of the CYP1A1 Ile462Val
polymorphism was verified by commercial sequencing
analysis of 10 % randomly selected samples.
2.3 Statistical Analysis
The differences in genotypic and allelic distribution
between patients and controls and their genotype deviation
from the Hardy–Weinberg (HW) equilibrium were evalu-
ated by the Chi-squared test. Moreover, the odds ratio (OR)
and 95 % confidence intervals (95 % CI) were calculated.
Unconditional logistic regression analysis was used to
adjust for the effect of confounders such as age, parity, oral
contraceptive use, tobacco smoking, and menopausal sta-
tus. A p-value of \0.05 was considered statistically
significant.
3 Results
3.1 Distribution of the CYP1A1 Ile462Val
Polymorphism in Women with Cervical Cancer
Prevalence of the CYP1A1 Ile462Val genotypes did not
display significant differences from the HW equilibrium
between patients and controls. The distribution and adjus-
ted analyses of the CYP1A1 Ile462Val genotypes in cases
and controls are presented in Table 2. The CYP1A1 Ile/Val
heterozygous genotype frequency was 1.5-fold greater in
women with cervical cancer compared with controls and
was 0.09 and 0.06, respectively. There were no individuals,
either patients or controls, with the homozygous CYP1A1
Val/Val genotype. The CYP1A1 Val allele frequency was
slightly increased in patients as compared with controls and
was 0.04 and 0.03, respectively. Logistic regression ana-
lysis demonstrated that the CYP1A1 Ile/Val polymorphism
was not associated with an increased risk of cervical can-
cer. The adjusted OR for patients with the Ile/Val genotype
vs. Ile/Ile genotype was 1.539 (95 % CI 0.932–2.541,
p = 0.091). However, stratification of the patients based on
the histologic type of cancer also did not show a contri-
bution of the CYP1A1 Ile/Val polymorphism with squa-
mous cell carcinoma, adenocarcinoma, or with tumor stage
and histologic grade (data not shown).
3.2 Stratified Analyses Between the CYP1A1
Ile462Val Polymorphism and Cervical Cancer
Risks
The age-adjusted assessment of the CYP1A1 Ile462Val
polymorphism and cervical cancer risk stratified by parity,
oral contraceptive use, tobacco smoking, and menopausal
status are listed in Table 3 and Fig. 1. An increase in
cervical cancer risk was seen among patients with a posi-
tive history of tobacco smoking and parity. In patients with
a positive history of tobacco smoking, the adjusted OR for
the Ile/Val vs. Ile/Ile genotype was 2.978 (95 % CI
1.382–6.418, p = 0.0052). The adjusted OR for parity in
patients with the Ile/Val vs. Ile/Ile genotype was 1.739
(95 % CI 1.006–3.009, p = 0.0472). However, no signifi-
cant association was seen between CYP1A1 Ile462Val and
patients with a positive history of oral contraceptive use
and menopausal women (Table 3; Fig. 1). Moreover, we
did not find an association between CYP1A1 Ile462Val and
tumor stage, histologic grade, and type (Table 4; Fig. 2).
4 Discussion
The CYP1A1 Ile462Val polymorphism has been shown to
be a risk factor for many types of cancer and hematopoietic
malignancies [14–21]. To date, the CYP1A1 Ile462Val
SNP has been shown to be a risk factor in the development
of pharyngeal, prostate, lung, oral, ovary, bladder, and
colorectal cancers [14–20]. In addition to these findings,
the CYP1A1 Ile462Val SNP has been suggested to be a
low-penetrant risk factor for acute leukemia [21]. There are
also studies suggesting that the CYP1A1 Ile462Val SNP
may be a risk factor for cervical cancer development
[11, 12]. However, we did not observe, in our study, the





OR (95 % CI) p-Valuea Adjusted OR
(95 % CI)b
p-Valuea
Ile/Ile 415 (0.91) 466 (0.94) Referent – Referent
Ile/Val 41 (0.09) 29 (0.06) 1.588 (0.9689–2.416) 0.0646 1.539 (0.932–2.541) 0.091
Val/Val 0 (0.00) 0 (0.00)
MAF 0.04 0.03
a Chi-square analysis
b ORs were adjusted by age, parity, oral contraceptive use, tobacco smoking, and menopausal status
CI confidence interval, OR odds ratio
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CYP1A1 Ile462Val polymorphism to be a risk factor of
cervical cancer in our patient group. Our results are similar
to those of Gutman et al. [10], who did not find an
increased risk for cervical cancer in the Jewish Israeli
population. Moreover, there was no significant association
between the CYP1A1 Ile462Val SNP and cervical cancer in
the Japanese population [13]. In contrast, the study
conducted by Taskiran et al. [11] in the Turkish population
demonstrated the CYP1A1 Val gene variant as a significant
risk factor of CIN 1 and 2 and for cervical adenocarcinoma
and squamous cell carcinoma. Joseph et al. [12] observed a
significant contribution of the CYP1A1 Ile462Val SNP to
cervical cancer, when adjusted for HPV status in Indian
populations. Moreover, the CYP1A1 Ile462Val polymor-
phism has been inconsistently shown to be a risk factor of
cervical cancer in the Chinese population [22–27]. In
addition to these findings, two recently conducted meta-
analyses have indicated that the Val gene variant may be a
risk factor in cervical cancer development in Caucasian but
not Asian populations [28, 29].
The use of tobacco has been recognized as a factor that
can increase the risk of numerous carcinomas, including
lung, larynx, mouth, esophagus, kidneys, urinary tract,
cervix, and others [30]. In our study, we found that the
CYP1A1 Ile462Val SNP increased the risk of cervical
cancer in women with a positive history of tobacco
smoking. Gutman et al. [10] demonstrated that tobacco
smoking is an independent risk factor for cervical cancer.
The human CYP1A1 enzyme is present in many epithelial
tissues and conducts oxidative reactions involved in the
bioactivation of tobacco’s aromatic hydrocarbons, aromatic
amines, and nitrosamines to carcinogens [7, 31]. These
substances interact with DNA leading to the formation of
DNA adducts, which make the carrier prone to carcino-
genesis [7, 31]. It has been demonstrated that tobacco
consumers bearing the CYP1A1 462Val variant possess
more polycyclic aromatic hydrocarbon-DNA adducts in
Table 3 Stratified analyses between the distribution of CYP1A1 Ile462Val genotypes and cervical cancer risks: pregnancy, oral contraceptive
use, tobacco smoking, and menopausal status
High-risk exposure Patients Controls Adjusted OR (95 % CI)a p-Valueb
Genotype Ile/Ile Ile /Val Ile/Ile Ile /Val
Parity
Ever 370 35 416 23 1.739 (1.006–3.009) 0.0472
Never 45 6 50 6 1.596 (0.441–5.773) 0.4709
Oral contraceptive use
Ever 187 21 205 12 1.923 (0.918–4,030) 0.0821
Never 228 20 261 17 1.370 (0.697–2.692) 0.3597
Smoking
Ever 134 27 154 10 2.978 (1.382–6.418) 0.0052
Never 281 14 312 19 1.338 (0.575–3.113) 0.4983
Menopausal status
Premenopausal 149 10 178 12 0.939 (0.391–2.257) 0.8885
Postmenopausal 266 31 288 17 1.857 (0.997–3.460) 0.0507
a (Ile /Val vs. Ile/Ile)
b Chi square analysis
All p-values were adjusted by age. Significant results are highlighted in bold font
CI confidence interval, OR odds ratio
Fig. 1 Adjusted odds ratio (OR) plot for genotyping frequencies of
the CYP1A1 Ile462Val polymorphism for patients stratified based on
parity, oral contraceptive use, tobacco smoking, and menopausal
status. Each OR value is represented by the corresponding black dot
with arms representing 95 % confidence intervals (95 % CI)
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white blood cells as compared with smokers without that
variant [32]. Although the CYP1A1 Ile462Val substitution
situated in the heme-binding region of the enzyme did not
change the enzyme’s activity in vitro, this substitution is
accompanied by a twofold increase in microsomal enzyme
activity [33, 34]. The CYP1A1 Ile462Val SNP has been
proposed to be in complete LD with the CYP1A1 T3801C
(rs4646903) polymorphism, which experimentally exhib-
ited up-regulation of enzymatic activity [9].
Moreover, we found a borderline risk for cervical cancer
in women with the Ile462Val SNP that had a positive
history of parity, which is in agreement with other studies
demonstrating parity as a risk factor for cervical cancer
[35]. It has been suggested that high parity might increase
the risk of cervical carcinoma owing to the many years of
transformation of the exocervical zone, leading this area to
become more susceptible to direct exposure to HPV and
carcinogens [35].
Table 4 Stratified analyses
between the distribution of
CYP1A1 Ile462Val genotypes
and clinical characteristics:
stage, histologic grade, and type
ORs for patients with histologic
grade Gx and unknown
histologic type of cervical
cancer were not calculated
a (Ile/Val vs. Ile/Ile)
b Chi square analysis
c Fisher exact test
CI confidence interval, OR odds
ratio




IA 55 6 1.753 (0.697–4.410) 0.2275
IB 57 6 1.691 (0.673–4.250) 0.2584
IIA 53 6 1.819 (0.722–4.583) 0.1982
IIB 49 6 1.968 (0.779–4.973) 0.1455
IIIA 139 9 1.040 (0.481–2.251) 0.9200
IIIB 48 5 1.674 (0.619–4.526) 0.3051
IVA 7 2 4.591 (0.912–23.107) 0.1006c
IVB 7 1 2.296 (0.273–19.300) 0.3907c
Histologic grade
G1 80 7 1.406 (0.596–3.319) 0.4347
G2 133 12 1.450 (0.720–2.920) 0.2958
G3 91 7 1.236 (0.525–2.908) 0.6267
Histologic type
Squamous cell carcinoma 353 31 1.407 (0.832–2.379) 0.2003
Adenocarcinoma 48 6 2.009 (0.794–5.081) 0.1336
Fig. 2 Adjusted odds ratio
(OR) plot for genotyping
frequencies of the CYP1A1
Ile462Val polymorphism for
patients with cervical cancer
stratified based on clinical
characteristics: stage, histologic
grade, and type. Each OR value
is represented by the
corresponding black dot with
arms representing 95 %
confidence intervals (95 % CI).
ORs for patients with histologic
grade Gx and unknown
histological type of cervical
cancer were not calculated
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Our genetic evaluation is the first to demonstrate that the
CYP1A1 Ile462Val polymorphism can be a risk factor for
cervical cancer in women with a positive history of tobacco
smoking and parity, therefore this study should be repli-
cated in other independent cohorts.
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